Otomicina

Quick links to important sections

Otomicina

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Otomicina

Property Description
Active Ingredients Chloramphenicol, Lidocaine Hydrochloride
Form Otic Solution (Ear Drops)
Pharmacological Class Otic Anti-infective and Local Anesthetic Combination
General Purpose Microbial Control and Symptomatic Pain Relief
Origin Synthetic

Otomicina is a synthetic, fixed-dose combination product specifically formulated as an Otic Solution, commonly referred to as ear drops, for topical (aural) administration. It is classified within the pharmacological class of an otic anti-infective and local anesthetic combination, meaning it delivers two distinct therapeutic actions in a single preparation. This product, often available under various brand names depending on the region, is clinically recognized for its dual-action approach in managing acute external ear discomfort.


What Type of Medicine is Otomicina?

Otomicina is a combination pharmaceutical preparation that is strictly designated for aural administration. This otic solution contrasts with single-agent ear drops because it integrates both an anti-infective agent and a local pain reliever. Chloramphenicol, as an antibiotic, is effective against a wide range of bacteria that can cause localized infections, confirming its utility in this common use scenario. This means the medicine is designed to effectively stop the growth of various common bacteria found in ear issues.


What are the Active Ingredients in Otomicina?

The preparation contains two active ingredients: Chloramphenicol and Lidocaine Hydrochloride. Chloramphenicol is the broad-spectrum antibiotic component, and its primary function is microbial control. The other component, Lidocaine Hydrochloride, is an amide-type local anesthetic whose role is to provide relief from localized discomfort and pain. Lidocaine has a quick onset of action when applied topically. This indicates that the preparation provides immediate relief from ear pain upon application, a key differentiator from antibiotic-only ear treatments.


What is the General Purpose of This Combination?

The general purpose of this specific combination is to simultaneously manage two common issues: the underlying infection and the associated acute pain. The Chloramphenicol ingredient is intended to stop the proliferation of susceptible bacteria, achieving microbial control, while the Lidocaine Hydrochloride provides an immediate local anesthesia effect to alleviate discomfort. This dual action ensures that the overall treatment strategy addresses both the microbial cause and the major symptom in one targeted, topical application.

What side effects are possible with Otomicina?

Possible side effects and safety information

The official safety information for this otic solution, which contains Chloramphenicol and Lidocaine, addresses both common local reactions and rare, serious systemic risks associated with the anti-infective component.

Adverse Reactions and Frequency

Adverse effects are categorized based on their documented occurrence in regulatory data:

  • Common Reactions: These are frequently observed, local effects at the application site. They include mild stinging, burning, irritation, itching, or redness in and around the ear.
  • Rare Reactions: These systemic effects are infrequently reported but are considered serious. They include potentially fatal blood dyscrasias, such as aplastic anaemia, associated with Chloramphenicol. Gray Syndrome, a severe systemic toxicity, is also documented as a rare risk, particularly concerning for infants.

Regulatory documents also list various forms of hypersensitivity reactions (e.g., angioedema) within the Immune System disorders class, for which the frequency is often listed as not precisely known.

Safety Considerations and Restrictions

The safety profile is structured around specific constraints documented in official labeling:

  • Population-Specific Risk: Regulatory texts highlight an increased risk of Gray Syndrome in neonates, premature infants, and infants, largely prohibiting or restricting its use in these youngest populations.
  • Exposure Patterns: A critical safety note is that serious systemic effects, such as aplastic anaemia, have been reported following both short-term and prolonged topical exposure, and the effect may occur weeks or months after stopping the treatment.
  • Absolute Restriction: This medicine is Contraindicated for use in individuals who have a perforated tympanic membrane (eardrum), as this creates a pathway for drug entry into the middle ear, and for patients with known sensitivity to either Chloramphenicol or Lidocaine.

The regulatory safety summary explicitly establishes that while temporary local irritation is common, the overall risk is defined by the rare, serious systemic blood risks that must be considered regardless of the topical route of administration.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Otomicina


Overdose from Otomicina, while generally considered unlikely due to the low content of active ingredients in the topical solution, is documented in regulatory labeling regarding potential systemic absorption from excessive exposure.

The anesthetic component, Lidocaine, can cause initial Central Nervous System (CNS) effects such as tinnitus, lightheadedness, blurred vision, and muscle twitching or tremors. Severe outcomes progress to convulsions, unconsciousness, cardiovascular collapse, and cardiac arrest. Systemic absorption of Chloramphenicol carries the serious risk of bone marrow depression and potentially fatal aplastic anaemia. Infants and children are noted as having increased sensitivity and face the specific risk of Gray syndrome, involving irregular breathing and cardiovascular changes.

Seek immediate medical attention or emergency care upon the occurrence of any sign of systemic toxicity or severe adverse reaction. Management involves providing supportive care and symptomatic treatment, as no specific antidote is documented for the components; dialysis is of negligible value for Lidocaine toxicity. Close monitoring of neurological and cardiovascular status is required during management.

Therapeutic Uses of Otomicina

What Otomicina Treats: Main Uses and Benefits

Otomicina is commonly used to help manage the dual challenges of acute external ear infection and the associated acute pain, is relevant for easing symptoms, and is applied in addressing infectious conditions. The therapeutic context of the anti-infective component aligns with the management and treatment of otitis externa.

The medication is applied across domains where additional symptomatic support is needed, addressing conditions presenting with acute episodes of ear discomfort and infection. This includes common scenarios like Swimmer's Ear, infectious processes of the external auditory canal, and painful inflammation caused by susceptible bacterial growth.

Symptom Management and Therapeutic Benefit

The primary benefit is in providing symptomatic relief for symptoms related to physical discomfort, such as sharp pain, stinging, burning, or throbbing sensations, while applied in addressing infectious conditions. The combined approach is relevant in clinical settings that involve acute or disruptive symptom patterns, as it supports the needed symptomatic relief and helps ease distress. This supports general well-being during symptomatic phases.

“The dual action is relevant in contexts involving short-term symptomatic support and conditions involving inflammatory or irritative processes.”

Therapeutic Focus: Symptom Relief

This medication is commonly used to help address symptom clusters that may become intense or disruptive, specifically acute ear pain (otalgia) linked to localized bacterial infection.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility and Contraindications for Otomicina

Official regulatory documents define the population that can use Otomicina by outlining specific contraindications and restrictions that prohibit its use in certain groups and clinical situations.

Populations That Must Not Use Otomicina (Contraindicated)

The medicine is strictly contraindicated and must not be used by individuals who fall into the following categories:

  • Hypersensitivity: Patients with a documented history of allergy or hypersensitivity to any of the active ingredients (such as a quinolone antibiotic or corticosteroid), or to any inactive component of the formulation.
  • Infections: Individuals with an external ear canal infection confirmed to be caused by a virus (e.g., Herpes simplex or Varicella) or a fungus.
  • Age: Infants younger than the minimum age specified in the product's official labeling (commonly 6 months or 1 year, depending on the specific regulatory document).

Eligibility Restrictions

Specific formulations of this product may also carry additional restrictions based on the patient’s physical condition:

  • Tympanic Membrane Status: Use may be restricted or entirely contraindicated if the eardrum is known or suspected to be perforated. The official labeling must be consulted for the specific product's restriction regarding the integrity of the tympanic membrane.
  • Physiological State: For pregnant and breastfeeding individuals, use is generally restricted unless the medical benefit is determined to outweigh the potential risk, as documented in the product's official eligibility status sections.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Otomicina is defined by the potential for additive effects and exposure modifications stemming from its two active components, Chloramphenicol and Lidocaine Hydrochloride, as documented in official regulatory sources.

Mandatory Restrictions

Co-administration with drugs liable to depress bone marrow function must be strictly avoided. This combination is classified as a contraindicated combination due to the theoretical risk of systemic absorption of Chloramphenicol, which may lead to bone marrow hypoplasia.

Pharmacodynamic and Exposure Effects

The Lidocaine component has documented pharmacodynamic interactions that can reinforce toxic effects. Concomitant use with Class I antiarrhythmic drugs (such as tocainide and mexiletine) or with other products containing local anesthetic agents may result in additive CNS and cardiovascular effects. Due to this additive risk, the total systemic exposure from all sources must be accounted for. Furthermore, the application of external heat sources to the administration site is restricted because it may increase the systemic exposure of the local anesthetic component.

Specific Constraints

Individuals with severe hepatic disease are at a greater risk of developing toxic blood concentrations of the Lidocaine component. This is a population-specific constraint noted in regulatory documents due to the role of the liver in metabolizing and clearing the local anesthetic. No mandatory timing separation rules or official interactions with food, alcohol, or supplements are documented for this product.

Mechanism of Action

Otomicina is a fixed-dose combination with two independent pharmacodynamic mechanisms attributed to its active components: chloramphenicol and lidocaine hydrochloride.

Chloramphenicol's action involves binding reversibly to the 50S ribosomal subunit within susceptible bacterial cells. This interaction type sterically hinders the peptidyl transferase enzyme, thereby preventing the crucial transpeptidation step required for peptide bond formation during protein synthesis. The resulting molecular pathway modulation is the inhibition of the elongation phase of translation, leading to a cascade that arrests bacterial growth and replication. The resultant system-level physiological consequence is bacteriostasis against target microorganisms.

Lidocaine acts by targeting the voltage-gated sodium channels located on the neuronal cell membrane. This interaction type stabilizes the neuronal membrane by blocking the rapid influx of sodium ions necessary for action potential generation and propagation. The downstream cascade is the cessation of nerve impulse transmission, which results in the temporary, localized suspension of peripheral sensory signaling.

Dosage and Administration Information

Administration of Otomicina

Otomicina is a topical medication specifically formulated for application within the external ear canal. Proper administration is necessary to ensure the solution reaches the affected area effectively.

Preparation

Before using the medication, it is important to clean the external ear canal gently to remove any excess debris or wax that might obstruct the passage of the drops. The hands should be washed thoroughly with soap and water before handling the bottle to prevent contamination of the dropper tip.

To minimize discomfort from the cold solution, the bottle may be held in the hand for a few minutes to bring the liquid closer to body temperature. The bottle should not be heated by external heat sources.

Application Technique

The following steps are typically used for the administration of ear drops:

  • Positioning: The individual should lie down or tilt the head so that the affected ear is facing upward.
  • Straightening the Canal: For adults, the earlobe is gently pulled upward and backward to straighten the ear canal. For children, the earlobe is typically pulled downward and backward.
  • Instillation: The prescribed number of drops is placed into the ear canal. The dropper tip must not touch the ear, fingers, or any other surface to maintain sterility.
  • Absorption: The head should remain tilted, or the individual should remain lying on their side, for several minutes. This allows the medication to flow down the length of the canal and remain in contact with the affected tissue.

Post-Application

Once the application is complete, the bottle should be closed tightly. If drops were prescribed for both ears, the process is repeated for the second ear after the appropriate absorption time has passed for the first.

Recent Clinical Evidence

Otomicina: Recent Clinical Evidence

Evidence for Use in Acute External Ear Infection

Research has explored the anti-infective component of Otomicina in Randomized Controlled Trials (RCTs) and Systematic Reviews to examine the anti-infective component in the context of bacterial external ear infections, a condition often called Otitis Externa. These studies monitored patients with uncomplicated, diffuse ear infections and examined outcomes such as the clinical cure rate (a measurement defined as the disappearance of all signs and symptoms) and the rate of clinical improvement (a measurement of symptom change).

The evidence for the anti-infective component was observed to be Moderate. Results apply only to the populations studied. Comparative evidence is lacking in some areas, and long-term effects are not fully established, as follow-up durations were limited to the short-term course of the infection.


Evidence for Acute Ear Pain Relief (Otalgia)

Research has also focused on the local anesthetic component, Lidocaine, which was studied for its application in cases of acute ear pain, or otalgia, associated with infection. Studies conducted during periods of increased symptom activity include Randomized Controlled Trials (RCTs) and Meta-analyses comparing the topical anesthetic drops to an inactive preparation or to usual care methods for ear pain. Research explored short-term symptom changes and examined patient-reported outcomes describing perceived discomfort.

Studies monitored measurements of pain intensity using numerical scales reported by patients or parents, and the time to pain reduction soon after the ear drops were administered. Findings describe patterns where outcomes related to physical discomfort were measured during the study period.

The evidence for the pain relief component was observed to be Moderate. The available data are sometimes limited because sample sizes were modest, and there is uncertainty regarding the precise contribution of the topical agent when a patient is also using oral pain medication.


Research Gaps and Areas of Uncertainty

The clinical research was evaluated in populations that included both adults and children. Results apply only to the populations studied, and data for certain groups remain insufficient. It is not yet clear whether the long-term effects of the medicine are fully established, as follow-up durations were limited in the key trials.

Frequently Asked Questions (FAQ)

Common questions about Otomicina (FAQ)


Q: Is Otomicina the same as ear drops I can buy over the counter?

According to official product information, Otomicina, which contains the antibiotic chloramphenicol, is typically classified as a prescription-only medicine. This classification means the product is intended for use under the guidance of a healthcare professional.


Q: How quickly does Otomicina usually start working to relieve pain?

The pain relief component of Otomicina is Lidocaine, a local anesthetic. Official pharmacological documents indicate that Lidocaine has a well-known rapid onset of action when applied topically, which suggests that symptomatic relief from ear pain typically occurs soon after application.


Q: Is it normal for my ear to feel a little itchy after using Otomicina?

Yes, regulatory documents list mild local effects such as itching, stinging, burning, or redness at the application site as common reactions. These sensations are generally temporary and are classified as common local effects.


Q: Are there any common foods or drinks that interact with Otomicina?

Official product labeling for Otomicina generally indicates that there are no known documented interactions between this topical otic solution and common food or drinks. Its topical administration limits the systemic exposure that often leads to food interactions.


Q: What should I do if I miss a dose of Otomicina?

Regulatory documents outline that a missed dose may be applied as soon as the omission is noted. However, if it is already nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed.


Q: Can Otomicina cause dizziness or lightheadedness?

While not listed as a common local reaction, regulatory safety documents report that dizziness or lightheadedness have occurred as side effects. These events are associated with the systemic absorption of the Lidocaine component in rare instances.


Q: What is the shelf life of Otomicina after the bottle has been opened?

To maintain the quality and sterility of the product, official storage and handling instructions require the solution to be discarded four weeks (28 days) after opening the bottle. The medicine must be kept in its original container as specified in the labeling.


Q: Why do doctors often prescribe ear drops instead of oral antibiotics for ear infections?

Otomicina is a topical treatment. As a topical route, it is primarily designed to deliver the medicine directly to the external ear canal. This localized treatment is often preferred for external ear infections to help limit the systemic absorption associated with oral antibiotics.


Q: Is a temporary stinging sensation normal when first applying Otomicina?

Yes, official safety information lists a mild stinging, burning, or irritation sensation at the application site as a common local effect. This temporary discomfort is recognized in regulatory documents.


Q: What should I avoid doing while on Otomicina treatment?

According to official regulatory warnings, patients should avoid co-administering any other drugs that depress bone marrow function. Additionally, the medicine is contraindicated (must not be used) if the eardrum is perforated.


Q: Can Otomicina affect my balance or hearing long-term?

Regulatory documents note that ototoxicity (damage to the ear structure or hearing) has been reported with topical chloramphenicol. Hearing loss or tinnitus (ringing in the ears) have also been reported as side effects. Such events are typically reported as rare and serious adverse reactions.


Q: Are there any documented cases of Otomicina causing severe allergic reactions?

Yes, official safety information lists various hypersensitivity reactions within the immune system disorders class. These include serious reactions such as angioedema, anaphylaxis, and urticaria. The safety information lists these serious reactions among potential adverse effects.


Q: Does Otomicina work for fungal ear infections?

No, Otomicina is strictly contraindicated (must not be used) if the external ear infection is confirmed to be caused by a fungus or a virus. The medicine is intended for bacterial infections that are sensitive to the antibiotic component.


Q: Can Otomicina make tinnitus (ringing in the ears) worse?

Regulatory safety information lists tinnitus (ringing in the ears) as a potential side effect associated with the use of the Lidocaine component. This is a potential adverse reaction noted in the product's official labeling.


Q: Is it possible to become resistant to Otomicina after repeated use?

Official warnings and precautions state that prolonged use should be avoided. This may increase the likelihood of sensitisation and the emergence of resistant organisms.


Q: Why might Otomicina not work for some people's ear infections?

According to the indications, Otomicina may not be effective if the ear infection is caused by pathogens that are not susceptible (sensitive) to the antibiotic component, Chloramphenicol. A lack of effectiveness can also indicate a non-bacterial infection.


Q: What kind of ear infections is Otomicina typically prescribed for?

Otomicina is indicated for the topical treatment of bacterial infection of the external ear, a condition commonly known as Otitis Externa. It is prescribed for infections caused by pathogens that are sensitive to the antibiotic in the solution.


Q: Can children use Otomicina?

The standard regimen is generally used for Adults, Children, and the Elderly. However, use in Infants is conditional and permitted only if considered essential by a physician due to established risk considerations for this age group.


Q: Is Otomicina safe to use during pregnancy?

Official regulatory documents indicate that the safety for use in pregnancy has not been established. The product is generally not recommended for use during pregnancy, as systemic absorption is possible and safety has not been fully established.


Q: Can I use Otomicina if my eardrum has a small hole or perforation?

No, the medicine is contraindicated (must not be used) if the eardrum is perforated (has a hole). This restriction is in place for patient safety.


Q: Are there any age restrictions for using Otomicina?

While the standard regimen includes adults and older children, the medicine is strictly contraindicated in infants or restricted to conditional use only. This is due to the established systemic risk profile in that age group.


Q: Are there any herbal supplements that should not be taken with Otomicina?

Official regulatory documents generally state there are no known specific interactions with food, alcohol, or herbal supplements for this topical ear drop solution.

How should Otomicina be stored and disposed of?

How to Store and Dispose of Otomicina

Otomicina (Chloramphenicol and Lidocaine Otic Solution) must be stored according to label instructions to maintain its integrity, typically at controlled room temperature or under refrigeration (2 C to 8 C), depending on the specific formulation. It is mandatory to protect the solution from light and not allow it to freeze.

Keep the medicine in its original, tightly closed container and out of the sight and reach of children.

Stability and Disposal

The solution must be discarded four weeks (28 days) after opening or immediately if supplied in a single-dose vial. For disposal of unused or expired medicine, follow official regulatory guidelines. The medicine should not be poured down any drain or flushed down the toilet. The preferred disposal method is through a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Otomicina found in:

A-Z Index: